P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO Volume : 5 Issue : 1 Year : 2021
EJMO. 2021; 5(1): 1-5 | DOI: 10.14744/ejmo.2020.67429

Interleukin-2 Level for Normal People and COVID-19 Infection: Is It Our Concern is COVID-19 Infection or Interleukin-2 Level Before the Infection?

Alqaisy Yazan1
1Institute for Studies on Scientific Research and Documentation Ringgold standard institution - Medical research Dubai UAE , Dubai 46333 United Arab Emirates

The newly discovered Coronavirus severe acute respiratory distress syndrome virus-19 (SARAS-COV-2, COVID-19) has become a pandemic issue across the globe. Until now, many investigations are taking place to look for specific, safe, and potent anti-viral agents. Upon transmission and entry into the human body, SARS-COV-2 Trigger multiple external players to be involved in the protection against the viral infection. These include Masks, Gloves, Sanitizing and social distancing. On the other hand, multiple internal body players to be involved in the protection against the viral infection. These include Angiotensin converting enzyme inhibitors or (ACEI) or Angiotensin receptor blockers or (ARB). Also, immune players to be involved in the fight against the viral infection. These include Vaccines, plasma from the Recovered patients and cellular immune players such as B, T and natural killer (NK) Cells, as well as the soluble Cytokines and Chemokines. In this review, we will propose the best way to protect ourselves against COVID-19 infection using Interleukin-2, based on evidences we have. Keywords: COVID-19, drugs, Helper-T cells, Interleukin 2, experimental autoimmune encephalomyelitis, Treg cells and natural killer cells.


Cite This Article

Yazan A. Interleukin-2 Level for Normal People and COVID-19 Infection: Is It Our Concern is COVID-19 Infection or Interleukin-2 Level Before the Infection?. EJMO. 2021; 5(1): 1-5

Corresponding Author: Alqaisy Yazan

Full Text PDF PDF Download
EJMO & EJMO